Automate Your Wheel Strategy on ILMN
With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ILMN
- Rev/Share 27.4808
- Book/Share 15.2628
- PB 8.8732
- Debt/Equity 1.0819
- CurrentRatio 1.4251
- ROIC 0.1203
- MktCap 20693704000.0
- FreeCF/Share 6.4551
- PFCF 20.5499
- PE 30.0527
- Debt/Assets 0.417
- DivYield 0
- ROE 0.2998
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ILMN | Daiwa Securities | Outperform | Neutral | -- | $94 | Aug. 12, 2025 |
| Downgrade | ILMN | Scotiabank | Sector Outperform | Sector Perform | -- | $125 | July 11, 2025 |
| Reiterated | ILMN | Citigroup | -- | Neutral | $130 | $90 | March 4, 2025 |
| Downgrade | ILMN | HSBC Securities | Buy | Hold | -- | $100 | Feb. 28, 2025 |
| Downgrade | ILMN | Barclays | Equal Weight | Underweight | $130 | $100 | Feb. 10, 2025 |
| Downgrade | ILMN | TD Cowen | Buy | Hold | $177 | $140 | Feb. 7, 2025 |
| Downgrade | ILMN | Citigroup | Buy | Neutral | $190 | $165 | Dec. 11, 2024 |
| Upgrade | ILMN | HSBC Securities | Hold | Buy | -- | $180 | Oct. 17, 2024 |
| Upgrade | ILMN | Argus | Hold | Buy | -- | -- | Aug. 28, 2024 |
| Upgrade | ILMN | Daiwa Securities | Neutral | Buy | $120 | $154 | Aug. 16, 2024 |
News
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally
Published: February 03, 2026 by: PRNewsWire
Sentiment: Neutral
Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom.
Read More
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.
Read More
Illumina completes acquisition of SomaLogic
Published: January 30, 2026 by: PRNewsWire
Sentiment: Neutral
Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.
Read More
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
REGN or ILMN: Which Is the Better Value Stock Right Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Illumina Gets Medicare Boost for Cancer Test, Shares Climb
Published: January 20, 2026 by: Benzinga
Sentiment: Positive
Illumina Inc. (NASDAQ: ILMN) shares are up on Tuesday following news that the company has secured reimbursement for its FDA-approved TruSight Oncology Comprehensive test.
Read More
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Published: January 20, 2026 by: PRNewsWire
Sentiment: Neutral
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Illumina unveils dataset to speed up AI-powered drug discovery
Published: January 13, 2026 by: Reuters
Sentiment: Positive
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.
Read More
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Published: January 13, 2026 by: PRNewsWire
Sentiment: Neutral
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.
Read More
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Read More
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
REGN vs. ILMN: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
REGN vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. As multiomic datasets grow rapidly in size and complexity, researchers need easy-to-use tools to integrate information across transcriptomics, genomics, proteomics, epigenetics, and more.
Read More
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains?
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Can These 5 Relative Price Strength Stocks Lead in 2026?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
U.S. stocks are heading toward the end of the year with clear momentum, as the major indexes continue to hover near record levels. While short-term pauses have appeared, they have been shallow, suggesting that investors are positioning for a constructive finish to the year and a positive handoff into the new one.
Read More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Published: December 11, 2025 by: PRNewsWire
Sentiment: Neutral
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.
Read More
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
Read More
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO , Nov. 12, 2025 /PRNewswire/ -- A study published today in Nature , authored by Illumina, Inc. (NASDAQ: ILMN) scientists and by collaborators from The University of Queensland demonstrates the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits …
Read More
ALKS or ILMN: Which Is the Better Value Stock Right Now?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alkermes (ALKS) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Published: November 10, 2025 by: PRNewsWire
Sentiment: Neutral
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the …
Read More
About Illumina, Inc. (ILMN)
- IPO Date 2000-07-28
- Website https://www.illumina.com
- Industry Medical - Diagnostics & Research
- CEO Jacob Thaysen
- Employees 8970